CME: Colorectal cancer (CRC) treatment and screening: therapeutic updates, best practices, and barriers to care
ACCREDITATION EXPIRED: May 12, 2016
Activity Description / Statement of Need:
In this online CME self-learning program:
Colorectal cancer (CRC) is the second-leading cause of cancer deaths in the U.S. Early detection can reduce CRC mortality by 15%-33%, and screening is widely recommended for average-risk adults beginning at age 50 years. Since the mid-1990s, the U.S. Preventive Services Task Force, American Cancer Society, and other groups have recommended four modalities for screening: fecal occult blood testing (FOBT), flexible sigmoidoscopy, colonoscopy, and barium enema. In recent years, some groups have also proposed newer screening technologies, such as stool DNA and computed tomographic colonography.
Despite proven efficacy and consistent guidelines, nationally, screening for CRC using any of the recommended tests occurs at lower rates than use of mammography for CRC screening, Pap testing for cervical cancer screening, and even prostate-specific antigen testing for prostate cancer screening. One out of every three eligible adults in the U.S. has not been screened.Patients’ barriers include: failure of a physician to recommend screening, scheduling difficulties, cost, lack of access to healthcare or insurance coverage, gaps in knowledge, disinterest, fear, embarrassment, perceived pain, and a lack of current symptoms or health problems. Although physician advice and awareness of the need for screening are important, barriers to screening are not homogenous across tests, and test-specific barriers warrant consideration in designing strategies to improve screening rates. Evidence that patients are more familiar with colonoscopy than with other modalities suggests an opportunity to improve screening rates by educating patients about alternative tests.
Agenda
|
Epidemiology of and risk factors for CRC
|
|
Screening for and treatment of CRC Guidelines for CRC screening
|
|
Barriers to optimal screening of CRC Sub-optimal screening
|
|
Treatment of CRC
|
|
Strategies to improve CRC screening and care
|
|
Summary, conclusions, and best practice recap |
Target Audience:
Healthcare professionals including: hematologists, oncologist, pathologists, radiologists, and other clinicians who are involved in providing diagnostic and therapeutic services for patients with CRC.
Commercial Support Disclosure: This program is supported by educational grants from Genentech and Otsuka Pharmaceuticals.
Release Date: May 12, 2014 -- Expiration Date: May 12, 2016
Faculty: Zev Wainberg, MD
Agenda
Learning Objectives
By the end of the session the participant will be able to:
- 1. Recognize and describe those characteristics that play a role in determining the staging, prognosis, and diagnosis of CRC.
- 2. Describe the challenges and barriers to care associated with screening and treating patients with CRC.
- 3. Distinguish between the most appropriate treatment approaches to CRC and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
- 4. Distinguish between the most appropriate treatment approaches to CRC and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
- 5. Summarize the risk-benefit profiles of current and emerging therapies for the treatment of CRC.
Accreditation
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Zev Wainberg, MD has no relevent financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC.
Commercial Support Disclosure: This program is supported by educational grants from Genentech and Otsuka Pharmaceuticals.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.